Atossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given an average recommendation of “Hold” by the five analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $36.3333.

Several research analysts have issued reports on the company. HC Wainwright upped their price target on Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Ascendiant Capital Markets dropped their price target on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Finally, Weiss Ratings raised Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd.

Hedge Funds Weigh In On Atossa Genetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. &PARTNERS purchased a new position in Atossa Genetics during the 4th quarter worth approximately $25,000. Hudson Bay Capital Management LP purchased a new position in Atossa Genetics during the 2nd quarter worth approximately $26,000. Gallagher Capital Advisors LLC purchased a new position in Atossa Genetics during the 3rd quarter worth approximately $27,000. JPMorgan Chase & Co. grew its position in Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Stock Performance

NASDAQ ATOS opened at $5.12 on Thursday. The stock has a market capitalization of $44.08 million, a P/E ratio of -1.60 and a beta of 1.25. Atossa Genetics has a 1 year low of $3.76 and a 1 year high of $19.35. The business’s fifty day moving average is $5.29 and its two-hundred day moving average is $7.44.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, research analysts forecast that Atossa Genetics will post -4.41 earnings per share for the current year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.